Prostate cancer screening requires a modern, nuanced approach to reverse the rising incidence of metastatic disease caused by outdated, overly cautious guidelines. While the United States Preventive Services Task Force previously discouraged routine PSA testing due to concerns over overtreatment and biopsy-related complications, the foundational PLCO trial data was significantly contaminated by widespread screening in the control group. Effective screening now relies on longitudinal PSA velocity and density trends rather than single-point values, supplemented by contrast-free MRI and safer, more accurate transperineal biopsies. Furthermore, clinicians must account for the PSA-suppressing effects of 5-alpha-reductase inhibitors like finasteride, which can otherwise mask warning signs and lead to delayed diagnoses. By integrating these precision medicine tools and utilizing active surveillance for low-risk cases, prostate cancer mortality can be drastically reduced, transforming a leading cause of cancer death into a manageable condition.
Sign in to continue reading, translating and more.
Continue
